Peter Barton Hutt
CIK 1171527 · last filed 2023-03-06
Peter Barton Hutt is a corporate insider who has filed 77 SEC Form 4 insider transactions across 14 companies since 2007. The most recent filing, for CNCE, was dated Mar 6, 2023. Across all open-market trades the lifetime net is −$8.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $56.3M across reported positions. 5 SEC filings were submitted jointly with Q Holdings, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
MRNA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | Director | 0 | $8.37 | $0 | -$275.1K | 14 | 2023-03-06 |
| IMMUNOMEDICS INC (IMMU) Delisted | Director | 0 | — | — | $0 | 5 | 2020-10-23 |
| MRNA | Director | 203,924 | $275.76 | $56.23M | -$5.80M | 3 | 2019-11-22 |
| Salarius Pharmaceuticals, Inc. (FLKS) Delisted | Director | 467 | — | — | $0 | 5 | 2018-07-26 |
| Cartesian Therapeutics, Inc. (SELB) Delisted | Director | — | $0.88 | — | $0 | 2 | 2018-06-19 |
| XOMA Royalty Corp (XOMA) Delisted | Director | — | $40.17 | — | $0 | 9 | 2017-05-22 |
| DNIB UNWIND, INC. (BIND) Delisted | Director | — | — | — | $0 | 2 | 2016-06-22 |
| MCRB | Director | — | $1.71 | — | $0 | 2 | 2016-06-17 |
| MOMENTA PHARMACEUTICALS INC (MNTA) Delisted | Director | 6,725 | — | — | -$1.88M | 10 | 2014-09-15 |
| ISTA PHARMACEUTICALS INC (ISTA) Delisted | Director | 4,932 | — | — | $0 | 5 | 2011-12-07 |
| Celera CORP (CRA) Delisted | Director | — | — | — | $0 | 3 | 2010-05-27 |
| INGN | Director | 15,419 | $6.04 | $93.1K | $0 | 3 | 2008-06-13 |
| MMRGlobal, Inc. (FVRL) Delisted | Director | — | — | — | $0 | 1 | 2007-06-21 |
| CV THERAPEUTICS INC (CVTX) Delisted | Director | — | — | — | $0 | 1 | 2007-06-04 |
Recent Filings
77 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-03-06 | CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | Mixed | −29,488 | $0 | EDGAR |
| 2022-10-18 | CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | Mixed | — | -$11.4K | EDGAR |
| 2022-06-13 | CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | Grant (A) | +16,400 | $0 | EDGAR |
| 2021-06-11 | CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | Grant (A) | +5,125 | $0 | EDGAR |
| 2020-10-23 | IMMUNOMEDICS INC (IMMU) Delisted | Disp (D) | −13,516 | $0 | EDGAR |
| 2020-09-01 | CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | Exer (M) | +3,539 | $13.4K | EDGAR |
| 2020-06-22 | IMMUNOMEDICS INC (IMMU) Delisted | Grant (A) | +3,718 | $0 | EDGAR |
| 2020-06-12 | CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-11-22 | MRNA | Mixed | — | -$4.03M | EDGAR |
| 2019-09-18 | MRNA | Mixed | — | -$1.76M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.